EDIT Company Profile and Key Details

Q: Who are the executives of EDIT?

Ron MoldaverInvestor RelationsMr. Harry R. Gill IIISenior Vice President of OperationsMr. Erick J. Lucera C.F.A., CPA, CFA, CPAChief Financial Officer & Executive Vice PresidentMr. James C. MullenExecutive ChairmanDr. Baisong Mei M.D., Ph.D.Senior Vice President & Chief Medical OfficerDr. Gilmore O'NeillPres, Chief Executive Officer & DirectorDr. Mark S. ShearmanExecutive Vice President & Chief Scientific OfficerDr. Mark S. Shearman Ph.D.Executive Vice President & Chief Scientific OfficerDr. Bruce E. Eaton Ph.D.Executive Vice President, Chief Technology Officer & Chief Bus. OfficerDr. George McDonald Church Ph.D.Co-Founder & Scientific Advisory Board MemberMr. Erick J. Lucera C.F.A., C.P.A., CFA, CPAChief Financial Officer & Executive Vice PresidentMs. Michelle RobertsonAdvisorDr. Feng Zhang Ph.D.Co-FounderDr. David R. Liu Ph.D.Co-Founder & Chair of Scientific Advisory BoardDr. J. Keith Joung M.D., Ph.D.Co-Founder

NASDAQ : EDIT

Editas Medicine

$3.23

0.15+4.87%

At Close 4:00 PM

68.13

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Editas Medicine, Inc. (EDIT) stock surged +4.87%, trading at $3.23 on NASDAQ, up from the previous close of $3.08. The stock opened at $3.04, fluctuating between $3.04 and $3.23 in the recent session.

Stock Snapshot

3.08

Prev. Close

495.68M

Market Cap

3.04

Day Low

-4.31

P/E Ratio

-0.75

EPS (TTM)

-1.68

Cash Flow per Share

3.04

Open

153.46M

Number of Shares

3.23

Day High

99.61%

Free Float in %

4.27

Book Value

1.39M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 04, 2026	3.04	3.23	3.04	3.23	1.39M
Sep 03, 2026	3.09	3.13	3.00	3.08	1.38M
Sep 02, 2026	3.09	3.23	2.98	3.08	1.68M
Sep 01, 2026	3.00	3.16	2.98	3.07	1.23M
Aug 31, 2026	3.12	3.14	3.03	3.06	2.07M
Aug 28, 2026	3.25	3.41	3.15	3.16	3.27M
Aug 27, 2026	3.17	3.37	3.15	3.30	2.67M
Aug 26, 2026	3.40	3.52	3.16	3.18	2.94M
Aug 25, 2026	3.05	3.33	3.05	3.28	4.21M
Aug 24, 2026	3.14	3.18	2.97	3.00	2.06M
Aug 21, 2026	2.98	3.25	2.95	3.11	2.11M
Aug 20, 2026	3.17	3.23	2.92	2.94	4.26M
Aug 19, 2026	3.01	3.30	2.99	3.25	9.63M
Aug 18, 2026	2.89	2.99	2.80	2.88	2.23M
Aug 17, 2026	2.80	2.90	2.77	2.84	2.11M
Aug 14, 2026	2.81	2.85	2.72	2.82	1.47M
Aug 13, 2026	2.85	2.90	2.81	2.81	1.24M
Aug 12, 2026	2.96	3.03	2.82	2.84	1.63M
Aug 11, 2026	2.84	2.99	2.83	2.95	1.91M
Aug 10, 2026	2.84	2.90	2.79	2.81	1.46M

Contact Details

Cambridge, MA 02141

United States

https://www.editasmedicine.com 617 401 9000

About Company

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Stock Peers

ARGX

-20.31-1.93%

argenx SE$1,033.15 REGN

-15.75-1.87%

Regeneron Pharmaceuticals, Inc.$827.72 VRTX

-11.84-2.12%

Vertex Pharmaceuticals Incorporated$546.12 MDGL

-1.53-0.28%

Madrigal Pharmaceuticals, Inc.$541.08 UTHR

-2.63-0.54%

United Therapeutics Corporation$487.61 ONC

-4.42-1.22%

BeOne Medicines AG$358.26 KRYS

-13.23-3.56%

Krystal Biotech, Inc.$358.24 PRAX

-3.34-0.94%

Praxis Precision Medicines, Inc.$351.81 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 LGND

-4.14-1.43%

Ligand Pharmaceuticals Incorporated$285.60

Frequently Asked Questions

What is the current Editas Medicine, Inc. (EDIT) stock price?

Editas Medicine, Inc. (NASDAQ: EDIT) stock price is $3.23 in the last trading session. During the trading session, EDIT stock reached the peak price of $3.23 while $3.04 was the lowest point it dropped to. The percentage change in EDIT stock occurred in the recent session was 4.87% while the dollar amount for the price change in EDIT stock was $0.15.

EDIT's industry and sector of operation?

The NASDAQ listed EDIT is part of Biotechnology industry that operates in the broader Healthcare sector. Editas Medicine, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of EDIT?

Ron Moldaver
Investor Relations
Mr. Harry R. Gill III
Senior Vice President of Operations
Mr. Erick J. Lucera C.F.A., CPA, CFA, CPA
Chief Financial Officer & Executive Vice President
Mr. James C. Mullen
Executive Chairman
Dr. Baisong Mei M.D., Ph.D.
Senior Vice President & Chief Medical Officer
Dr. Gilmore O'Neill
Pres, Chief Executive Officer & Director
Dr. Mark S. Shearman
Executive Vice President & Chief Scientific Officer
Dr. Mark S. Shearman Ph.D.
Executive Vice President & Chief Scientific Officer
Dr. Bruce E. Eaton Ph.D.
Executive Vice President, Chief Technology Officer & Chief Bus. Officer
Dr. George McDonald Church Ph.D.
Co-Founder & Scientific Advisory Board Member
Mr. Erick J. Lucera C.F.A., C.P.A., CFA, CPA
Chief Financial Officer & Executive Vice President
Ms. Michelle Robertson
Advisor
Dr. Feng Zhang Ph.D.
Co-Founder
Dr. David R. Liu Ph.D.
Co-Founder & Chair of Scientific Advisory Board
Dr. J. Keith Joung M.D., Ph.D.
Co-Founder

How EDIT did perform over past 52-week?

EDIT's closing price is 94.58% higher than its 52-week low of $1.66 where as its distance from 52-week high of $4.54 is -28.81%.

How many employees does EDIT have?

Number of EDIT employees currently stands at 87.

Link for EDIT official website?

Official Website of EDIT is: https://www.editasmedicine.com

How do I contact EDIT?

EDIT could be contacted at phone 617 401 9000 and can also be accessed through its website. EDIT operates from 11 Hurley Street, Cambridge, MA 02141, United States.

How many shares of EDIT are traded daily?

EDIT stock volume for the day was 1.39M shares. The average number of EDIT shares traded daily for last 3 months was 2.35M.

What is the market cap of EDIT currently?

The market value of EDIT currently stands at $495.68M with its latest stock price at $3.23 and 153.46M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	87
Beta	2.06
Sales or Revenue	$78.12M
5Y Sales Change%	0.517%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	87
Beta	2.06
Sales or Revenue	$78.12M
5Y Sales Change%	0.517%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

EDIT Company Profile and Key Details

Editas Medicine

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Company Overview

Earnings & Analyst Outlook

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Key Takeaways

Price Forecast & Outlook